

Inflectra[®], Remicade[®] & Renflexis[®] Prior Authorization Request Form (Page 1 of 2)

Memb	per Information	(required)	Provider Information (required)					
Member Name:			Provider Name:					
Insurance ID#:			NPI#: Specialty:					
Date of Birth:			Office Phone:					
Street Address:			Office Fax:					
City:	y: State: Zip:			Office Street Address:				
Phone:			City: State: Zip:		Zip:			
		Medication Info	rmation (required)					
Medication Name:			Strength: Dosage Form		orm:			
Check if requesting	brand		Directions for Use:					
Check if request is	for continuation of the	rapy						
Clinical Information (required)								
Select the diagnosis below: Active ankylosing spondylitis Active psoriatic arthritis Chronic severe plaque psoriasis Crohn's disease Moderately to severely active rheumatoid arthritis Moderately to severely active ulcerative colitis Sarcoidosis Other diagnosis: ICD-10 Code(s):								
Select if Inflectra is prescribed by or in consultation with one of the following specialists, if applicable for the patient's diagnosis: Dermatologist Gastroenterologist Rheumatologist Pulmonologist Select if infliximab be used in combination with the following: Biologic DMARD [e.g., Enbrel (etanercept), Rituxan (rituximab), Orencia (abatacept), Kineret (anakinra), Cimzia (certolizumab)] Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)] Not in combination with a biologic DMARD or janus kinase inhibitor For Inflectra and Renflexis requests only: Does the patient have history of failure, contraindication, or intolerance to Remicade? Yes Doe								
For active ankylosing spondylitis, also answer the following: Does the patient have history of failure, contraindication, or intolerance to two non-steroidal anti-inflammatory drugs (NSAIDs)? I Yes I No								
For Crohn's disease, also answer the following:								
 Select if the patient has one of the following diagnoses: Fistulizing Crohn's disease Moderately to severely active Crohn's disease Select if the patient has history of failure, contraindication, or intolerance to the following: 6-mercaptopurine (Purinethol) Azathioprine (Imuran) Corticosteroids (e.g., prednisone, methylprednisolone) 								
 Controsteroids (e.g., prednisole, methylprednisolone) Methotrexate (Rheumatrex, Trexall) 								

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of ProAct. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. If you are not the intended recipient, please notify the sender immediately.

Office use only: Inflectra-Remicade-Renflexis_Jan_2018



1230 US Highway 11 Gouverneur, NY 13642 Phone: 1-877-635-9545 Prior Authorization Fax: 1-844-712-8129

Inflectra[®], Remicade[®] & Renflexis[®] Prior Authorization Request Form (Page 2 of 2)

For moderately to severely active rheumatoid arthritis, also answer the following:					
Is the patient receiving concurrent therapy with methotrexate (Rheumatrex, Trexall)? Yes No					
Does the patient have history of failure, contraindication, or intolerance to methotrexate (Rheumatrex, Trexall)? 🗖 Yes 🗅 No					
For moderately to severely active ulcerative colitis, also answer the following:					
 Select if the patient has history of failure, contraindication, or intolerance to the following: 6-mercaptopurine (Purinethol) Aminosalicylate [e.g., mesalamine (Asacol, Pentasa, Rowasa), olsalazine (Dipentum), sulfasalazine (Azulfidine, Sulfazine)] Azathioprine (Imuran) Corticosteroids (e.g., prednisone, methylprednisolone) 					
For sarcoidosis, also answer the following:					
Does the patient have history of failure, contraindication, or intolerance to corticosteroids (e.g., prednisone)? 🗖 Yes 🗅 No					
Does the patient have history of failure, contraindication, or intolerance to one immunosuppressant [e.g., methotrexate (Rheumatrex, Trexall), Cytoxan (cyclophosphamide), or Imuran (azathioprine)]? U Yes U No					
Reauthorization:					
If this is a reauthorization request, answer the following questions:					
Is there documentation the patient has had a positive clinical response to infliximab therapy? D Yes D No					
Is there documentation the patient has had a positive clinical response to infliximab therapy? U Yes U No					
Is there documentation the patient has had a positive clinical response to infliximab therapy? Select if infliximab be used in combination with the following: Biologic DMARD [e.g., Enbrel (etanercept), Rituxan (rituximab), Orencia (abatacept), Kineret (anakinra), Cimzia (certolizumab)] Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)] Not in combination with a biologic DMARD or janus kinase inhibitor					
Select if infliximab be used in combination with the following: Biologic DMARD [e.g., Enbrel (etanercept), Rituxan (rituximab), Orencia (abatacept), Kineret (anakinra), Cimzia (certolizumab)] Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]					

<u>Please note</u>: This request may be denied unless all required information is received.

Please fax this form to 1-844-712-8129 to initiate a prior authorization review for the member and medication above. Please note: plan benefits may limit or exclude coverage of specific medications including those requested on this form.

I certify, to the best of my knowledge, the statements and information provided on this form are factual and correct.

Provider/Representative (and Title):

C

Tra 1st Date:

PROACT INTERNAL USE ONLY:								
nical Review Decision								
	Approved, through							
	Denied (documentation attached, if necessary)							
acking:								
Attemp	t	2 nd Attempt		Letter Mailed:				

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of ProAct. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.** Office use only: Inflectra-Remicade-Renflexis_Jan_2018